BPG is committed to discovery and dissemination of knowledge
Cited by in F6Publishing
For: Filimoniuk A, Daniluk U, Samczuk P, Wasilewska N, Jakimiec P, Kucharska M, Lebensztejn DM, Ciborowski M. Metabolomic profiling in children with inflammatory bowel disease. Adv Med Sci 2020;65:65-70. [PMID: 31901795 DOI: 10.1016/j.advms.2019.12.009] [Cited by in Crossref: 13] [Cited by in F6Publishing: 13] [Article Influence: 6.5] [Reference Citation Analysis]
Number Citing Articles
1 Tian Z, Zhuang X, Zhuo S, Zhu Y, Hu S, Zhao M, Tang C, Zhang Z, Li X, Ma R, Zeng Z, Feng R, Chen M. Dietary inflammatory potential mediated gut microbiota and metabolite alterations in Crohn's disease: A fire-new perspective. Clinical Nutrition 2022. [DOI: 10.1016/j.clnu.2022.04.014] [Reference Citation Analysis]
2 Yu XH, Cao RR, Yang YQ, Lei SF. Identification of causal metabolites related to multiple autoimmune diseases. Hum Mol Genet 2021:ddab273. [PMID: 34523675 DOI: 10.1093/hmg/ddab273] [Reference Citation Analysis]
3 Khan F, Radovanovic A, Gojobori T, Kaur M. IBDDB: a manually curated and text-mining-enhanced database of genes involved in inflammatory bowel disease. Database (Oxford) 2021;2021:baab022. [PMID: 33929018 DOI: 10.1093/database/baab022] [Cited by in Crossref: 1] [Article Influence: 1.0] [Reference Citation Analysis]
4 Rycyk A, Cudowska B, Lebensztejn DM. Eosinophil-Derived Neurotoxin, Tumor Necrosis Factor Alpha, and Calprotectin as Non-Invasive Biomarkers of Food Protein-Induced Allergic Proctocolitis in Infants. J Clin Med 2020;9:E3147. [PMID: 33003355 DOI: 10.3390/jcm9103147] [Cited by in Crossref: 2] [Cited by in F6Publishing: 2] [Article Influence: 1.0] [Reference Citation Analysis]
5 Salvador-Martín S, Melgarejo-Ortuño A, López-Fernández LA. Biomarkers for Optimization and Personalization of Anti-TNFs in Pediatric Inflammatory Bowel Disease. Pharmaceutics 2021;13:1786. [PMID: 34834201 DOI: 10.3390/pharmaceutics13111786] [Reference Citation Analysis]
6 Bauset C, Gisbert-Ferrándiz L, Cosín-Roger J. Metabolomics as a Promising Resource Identifying Potential Biomarkers for Inflammatory Bowel Disease. J Clin Med 2021;10:622. [PMID: 33562024 DOI: 10.3390/jcm10040622] [Cited by in Crossref: 3] [Cited by in F6Publishing: 2] [Article Influence: 3.0] [Reference Citation Analysis]
7 Mojsak P, Rey-Stolle F, Parfieniuk E, Kretowski A, Ciborowski M. The role of gut microbiota (GM) and GM-related metabolites in diabetes and obesity. A review of analytical methods used to measure GM-related metabolites in fecal samples with a focus on metabolites' derivatization step. J Pharm Biomed Anal 2020;191:113617. [PMID: 32971497 DOI: 10.1016/j.jpba.2020.113617] [Cited by in Crossref: 4] [Cited by in F6Publishing: 3] [Article Influence: 2.0] [Reference Citation Analysis]
8 Szeremeta M, Pietrowska K, Niemcunowicz-Janica A, Kretowski A, Ciborowski M. Applications of Metabolomics in Forensic Toxicology and Forensic Medicine. Int J Mol Sci 2021;22:3010. [PMID: 33809459 DOI: 10.3390/ijms22063010] [Cited by in F6Publishing: 1] [Reference Citation Analysis]
9 Filimoniuk A, Blachnio-Zabielska A, Imierska M, Lebensztejn DM, Daniluk U. Sphingolipid Analysis Indicate Lactosylceramide as a Potential Biomarker of Inflammatory Bowel Disease in Children. Biomolecules 2020;10:E1083. [PMID: 32708181 DOI: 10.3390/biom10071083] [Cited by in Crossref: 4] [Cited by in F6Publishing: 5] [Article Influence: 2.0] [Reference Citation Analysis]
10 Jakimiec P, Zdanowicz K, Kwiatek-Sredzinska K, Filimoniuk A, Lebensztejn D, Daniluk U. Pancreatic Disorders in Children with Inflammatory Bowel Disease. Medicina (Kaunas) 2021;57:473. [PMID: 34064706 DOI: 10.3390/medicina57050473] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 1.0] [Reference Citation Analysis]
11 Imierska M, Kurianiuk A, Błachnio-Zabielska A. The Influence of Physical Activity on the Bioactive Lipids Metabolism in Obesity-Induced Muscle Insulin Resistance. Biomolecules 2020;10:E1665. [PMID: 33322719 DOI: 10.3390/biom10121665] [Cited by in Crossref: 3] [Cited by in F6Publishing: 2] [Article Influence: 1.5] [Reference Citation Analysis]
12 Beck LC, Granger CL, Masi AC, Stewart CJ. Use of omic technologies in early life gastrointestinal health and disease: from bench to bedside. Expert Rev Proteomics 2021;18:247-59. [PMID: 33896313 DOI: 10.1080/14789450.2021.1922278] [Reference Citation Analysis]
13 Grochowski ET, Pietrowska K, Kowalczyk T, Mariak Z, Kretowski A, Ciborowski M, Dmuchowska DA. Omics in Myopia. J Clin Med 2020;9:E3464. [PMID: 33126435 DOI: 10.3390/jcm9113464] [Cited by in F6Publishing: 1] [Reference Citation Analysis]
14 Yamamoto M, Shanmuganathan M, Hart L, Pai N, Britz-McKibbin P. Urinary Metabolites Enable Differential Diagnosis and Therapeutic Monitoring of Pediatric Inflammatory Bowel Disease. Metabolites 2021;11:245. [PMID: 33921143 DOI: 10.3390/metabo11040245] [Cited by in F6Publishing: 1] [Reference Citation Analysis]
15 Wang Y, Gao X, Zhang X, Xiao F, Hu H, Li X, Dong F, Sun M, Xiao Y, Ge T, Li D, Yu G, Liu Z, Zhang T. Microbial and metabolic features associated with outcome of infliximab therapy in pediatric Crohn's disease. Gut Microbes 2021;13:1-18. [PMID: 33430702 DOI: 10.1080/19490976.2020.1865708] [Cited by in Crossref: 5] [Cited by in F6Publishing: 6] [Article Influence: 5.0] [Reference Citation Analysis]
16 Daniluk U, Kwiatek-Sredzinska K, Jakimiec P, Daniluk J, Czajkowska A, Lebensztejn DM. Liver Pathology in Children with Diagnosed Inflammatory Bowel Disease-A Single Center Experience. J Clin Med 2021;10:5359. [PMID: 34830641 DOI: 10.3390/jcm10225359] [Reference Citation Analysis]
17 Zdanowicz K, Kucharska M, Reszec J, Lebensztejn DM, Daniluk U. Immunohistochemical markers for eosinophilic esophagitis. Scand J Gastroenterol 2020;55:1277-83. [PMID: 33032462 DOI: 10.1080/00365521.2020.1831053] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 0.5] [Reference Citation Analysis]